LRRK2, a puzzling protein: Insights into Parkinson's disease pathogenesis

Experimental Neurology

Volumn 261, Issue , 2014, Pages 206-216

  Esteves, A Raquel ^a   Swerdlow, Russell H ^b   Cardoso, Sandra M ^a,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Intracellular traffic; LRRK2; Mitochondria; Parkinson's disease; Quality control mechanisms

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; GUANOSINE TRIPHOSPHATASE; LEUCINE RICH REPEAT KINASE 2; PHOSPHOTRANSFERASE; PROTEASOME; UBIQUITIN; LRRK2 PROTEIN, HUMAN; LYSOSOMAL PROTEINS; PROTEIN; PROTEIN SERINE THREONINE KINASE;

AUTOPHOSPHORYLATION; CELL FUNCTION; CYTOSKELETON; DOPAMINE METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; GENE MUTATION; HUMAN; IMMUNE SYSTEM; INTRACELLULAR TRANSPORT; LYSOSOME; MITOCHONDRION; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN QUALITY; REVIEW; ANIMAL; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MUTATION; PATHOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; CYTOSKELETON; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MITOCHONDRIA; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; PROTEINS;

EID: 84905511765     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.05.025     Document Type: Review

References (168)

1. Alegre-Abarrategui J., Ansorge O., Esiri M., Wade-Martins R. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Neuropathol. Appl. Neurobiol. 2008, 34:272-283.
2. Alegre-Abarrategui J., Christian H., Lufino M.M., Mutihac R., Venda L.L., Ansorge O., Wade-Martins R. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet. 2009, 18:4022-4034.
3. Andres-Mateos E., Mejias R., Sasaki M., Li X., Lin B.M., Biskup S., Zhang L., Banerjee R., Thomas B., Yang L., Liu G., Beal M.F., Huso D.L., Dawson T.M., Dawson V.L. Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). J. Neurosci. 2009, 29:15846-15850.
4. Angeles D.C., Gan B.H., Onstead L., Zhao Y., Lim K.L., Dachsel J., Melrose H., Farrer M., Wszolek Z.K., Dickson D.W., Tan E.K. Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Hum. Mutat. 2011, 32:1390-1397.
5. Bailey R.M., Covy J.P., Melrose H.L., Rousseau L., Watkinson R., Knight J., Miles S., Farrer M.J., Dickson D.W., Giasson B.I., Lewis J. LRRK2 phosphorylates novel tau epitopes and promotes tauopathy. Acta Neuropathol. 2013, 126:809-827.
6. Berger Z., Smith K.A., Lavoie M.J. Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry 2010, 49:5511-5523.
7. Biosa A., Trancikova A., Civiero L., Glauser L., Bubacco L., Greggio E., Moore D.J. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2. Hum. Mol. Genet. 2013, 22:1140-1156.
8. Biskup S., West A.B. Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim. Biophys. Acta 2009, 1792:625-633.
9. Biskup S., Moore D.J., Celsi F., Higashi S., West A.B., Andrabi S.A., Kurkinen K., Yu S.W., Savitt J.M., Waldvogel H.J., Faull R.L., Emson P.C., Torp R., Ottersen O.P., Dawson T.M., Dawson V.L. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 2006, 60:557-569.
10. Bosgraaf L., Van Haastert P.J. Roc, a Ras/GTPase domain in complex proteins. Biochim. Biophys. Acta 2003, 1643:5-10.
11. Bravo-San Pedro J.M., Niso-Santano M., Gomez-Sanchez R., Pizarro-Estrella E., Aiastui-Pujana A., Gorostidi A., Climent V., Lopez de Maturana R., Sanchez-Pernaute R., Lopez de Munain A., Fuentes J.M., Gonzalez-Polo R.A. The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway. Cell. Mol. Life Sci. 2013, 70:121-136.
12. Caesar M., Zach S., Carlson C.B., Brockmann K., Gasser T., Gillardon F. Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration. Neurobiol. Dis. 2013, 54:280-288.
13. Carballo-Carbajal I., Weber-Endress S., Rovelli G., Chan D., Wolozin B., Klein C.L., Patenge N., Gasser T., Kahle P.J. Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. Cell. Signal. 2010, 22:821-827.
14. Chen C.Y., Weng Y.H., Chien K.Y., Lin K.J., Yeh T.H., Cheng Y.P., Lu C.S., Wang H.L. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Cell Death Differ. 2012, 19:1623-1633.
15. Cherra S.J., Steer E., Gusdon A.M., Kiselyov K., Chu C.T. Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons. Am. J. Pathol. 2013, 182:474-484.
16. Collins L.M., Toulouse A., Connor T.J., Nolan Y.M. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology 2012, 62:2154-2168.
17. Cookson M.R. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat. Rev. Neurosci. 2010, 11:791-797.
18. Cooper O., Seo H., Andrabi S., Guardia-Laguarta C., Graziotto J., Sundberg M., McLean J.R., Carrillo-Reid L., Xie Z., Osborn T., Hargus G., Deleidi M., Lawson T., Bogetofte H., Perez-Torres E., Clark L., Moskowitz C., Mazzulli J., Chen L., Volpicelli-Daley L., Romero N., Jiang H., Uitti R.J., Huang Z., Opala G., Scarffe L.A., Dawson V.L., Klein C., Feng J., Ross O.A., Trojanowski J.Q., Lee V.M., Marder K., Surmeier D.J., Wszolek Z.K., Przedborski S., Krainc D., Dawson T.M., Isacson O. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci. Transl. Med. 2012, 4:141ra190.
19. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
20. Dagda R.K., Zhu J., Kulich S.M., Chu C.T. Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease. Autophagy 2008, 4:770-782.
21. Dagda R.K., Cherra S.J., Kulich S.M., Tandon A., Park D., Chu C.T. Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J. Biol. Chem. 2009, 284:13843-13855.
22. Deng J., Lewis P.A., Greggio E., Sluch E., Beilina A., Cookson M.R. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:1499-1504.
23. Deng X., Dzamko N., Prescott A., Davies P., Liu Q., Yang Q., Lee J.D., Patricelli M.P., Nomanbhoy T.K., Alessi D.R., Gray N.S. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat. Chem. Biol. 2011, 7:203-205.
24. Ding X., Goldberg M.S. Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP. PLoS One 2009, 4:e5949.
25. Dodson M.W., Zhang T., Jiang C., Chen S., Guo M. Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum. Mol. Genet. 2012, 21:1350-1363.
26. Doggett E.A., Zhao J., Mork C.N., Hu D., Nichols R.J. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition. J. Neurochem. 2012, 120:37-45.
27. Dzamko N., Deak M., Hentati F., Reith A.D., Prescott A.R., Alessi D.R., Nichols R.J. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem. J. 2010, 430:405-413.
28. Estrada A.A., Liu X., Baker-Glenn C., Beresford A., Burdick D.J., Chambers M., Chan B.K., Chen H., Ding X., DiPasquale A.G., Dominguez S.L., Dotson J., Drummond J., Flagella M., Flynn S., Fuji R., Gill A., Gunzner-Toste J., Harris S.F., Heffron T.P., Kleinheinz T., Lee D.W., Le Pichon C.E., Lyssikatos J.P., Medhurst A.D., Moffat J.G., Mukund S., Nash K., Scearce-Levie K., Sheng Z., Shore D.G., Tran T., Trivedi N., Wang S., Zhang S., Zhang X., Zhao G., Zhu H., Sweeney Z.K. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J. Med. Chem. 2012, 55:9416-9433.
29. Ferree A., Guillily M., Li H., Smith K., Takashima A., Squillace R., Weigele M., Collins J.J., Wolozin B. Regulation of physiologic actions of LRRK2: focus on autophagy. Neurodegener. Dis. 2012, 10:238-241.
30. Gallo K.A., Johnson G.L. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Cell Biol. 2002, 3:663-672.
31. Gandhi P.N., Wang X., Zhu X., Chen S.G., Wilson-Delfosse A.L. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J. Neurosci. Res. 2008, 86:1711-1720.
32. Gandhi P.N., Chen S.G., Wilson-Delfosse A.L. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease. J. Neurosci. Res. 2009, 87:1283-1295.
33. Gardet A., Benita Y., Li C., Sands B.E., Ballester I., Stevens C., Korzenik J.R., Rioux J.D., Daly M.J., Xavier R.J., Podolsky D.K. LRRK2 is involved in the IFN-gamma response and host response to pathogens. J. Immunol. 2010, 185:5577-5585.
34. Geisler S., Holmstrom K.M., Skujat D., Fiesel F.C., Rothfuss O.C., Kahle P.J., Springer W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 2010, 12:119-131.
35. Gillardon F. Interaction of elongation factor 1-alpha with leucine-rich repeat kinase 2 impairs kinase activity and microtubule bundling in vitro. Neuroscience 2009, 163:533-539.
36. Gillardon F. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability-a point of convergence in parkinsonian neurodegeneration?. J. Neurochem. 2009, 110:1514-1522.
37. Gillardon F., Schmid R., Draheim H. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 2012, 208:41-48.
38. Gloeckner C.J., Schumacher A., Boldt K., Ueffing M. The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J. Neurochem. 2009, 109:959-968.
39. Gloeckner C.J., Boldt K., von Zweydorf F., Helm S., Wiesent L., Sarioglu H., Ueffing M. Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. J. Proteome Res. 2010, 9:1738-1745.
40. Gomez-Suaga P., Luzon-Toro B., Churamani D., Zhang L., Bloor-Young D., Patel S., Woodman P.G., Churchill G.C., Hilfiker S. Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum. Mol. Genet. 2012, 21:511-525.
41. Gotthardt K., Weyand M., Kortholt A., Van Haastert P.J., Wittinghofer A. Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO J. 2008, 27:2352.
42. Greggio E. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease. Biochem. Soc. Trans. 2012, 40:1058-1062.
43. Greggio E., Cookson M.R. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 2009, 1.
44. Greggio E., Singleton A. Kinase signaling pathways as potential targets in the treatment of Parkinson's disease. Expert Rev. Proteomics 2007, 4:783-792.
45. Greggio E., Jain S., Kingsbury A., Bandopadhyay R., Lewis P., Kaganovich A., van der Brug M.P., Beilina A., Blackinton J., Thomas K.J., Ahmad R., Miller D.W., Kesavapany S., Singleton A., Lees A., Harvey R.J., Harvey K., Cookson M.R. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 2006, 23:329-341.
46. Greggio E., Zambrano I., Kaganovich A., Beilina A., Taymans J.M., Daniels V., Lewis P., Jain S., Ding J., Syed A., Thomas K.J., Baekelandt V., Cookson M.R. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J. Biol. Chem. 2008, 283:16906-16914.
47. Greggio E., Taymans J.M., Zhen E.Y., Ryder J., Vancraenenbroeck R., Beilina A., Sun P., Deng J., Jaffe H., Baekelandt V., Merchant K., Cookson M.R. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem. Biophys. Res. Commun. 2009, 389:449-454.
48. Guerreiro P.S., Huang Y., Gysbers A., Cheng D., Gai W.P., Outeiro T.F., Halliday G.M. LRRK2 interactions with alpha-synuclein in Parkinson's disease brains and in cell models. J. Mol. Med. (Berl) 2012, 91(4):513-522.
49. Guo L., Gandhi P.N., Wang W., Petersen R.B., Wilson-Delfosse A.L., Chen S.G. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp. Cell Res. 2007, 313:3658-3670.
50. Guse A.H., Lee H.C. NAADP: a universal Ca2+ trigger. Sci. Signal. 2008, 1:re10.
51. Hakimi M., Selvanantham T., Swinton E., Padmore R.F., Tong Y., Kabbach G., Venderova K., Girardin S.E., Bulman D.E., Scherzer C.R., LaVoie M.J., Gris D., Park D.S., Angel J.B., Shen J., Philpott D.J., Schlossmacher M.G. Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J. Neural Transm. 2011, 118:795-808.
52. Han B.S., Iacovitti L., Katano T., Hattori N., Seol W., Kim K.S. Expression of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigra. Neurosci. Lett. 2008, 442:190-194.
53. Haugarvoll K., Wszolek Z.K. Clinical features of LRRK2 parkinsonism. Parkinsonism Relat. Disord. 2009, 15(Suppl. 3):S205-S208.
54. Heo H.Y., Kim K.S., Seol W. Coordinate regulation of neurite outgrowth by LRRK2 and its interactor, Rab5. Exp. Neurobiol. 2010, 19:97-105.
55. Heo H.Y., Park J.M., Kim C.H., Han B.S., Kim K.S., Seol W. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity. Exp. Cell Res. 2010, 316:649-656.
56. Herrera A.J., Castano A., Venero J.L., Cano J., Machado A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol. Dis. 2000, 7:429-447.
57. Higashi S., Biskup S., West A.B., Trinkaus D., Dawson V.L., Faull R.L., Waldvogel H.J., Arai H., Dawson T.M., Moore D.J., Emson P.C. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res. 2007, 1155:208-219.
58. Higashi S., Moore D.J., Colebrooke R.E., Biskup S., Dawson V.L., Arai H., Dawson T.M., Emson P.C. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J. Neurochem. 2007, 100:368-381.
59. Higashi S., Moore D.J., Yamamoto R., Minegishi M., Sato K., Togo T., Katsuse O., Uchikado H., Furukawa Y., Hino H., Kosaka K., Emson P.C., Wada K., Dawson V.L., Dawson T.M., Arai H., Iseki E. Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease. J. Neuropathol. Exp. Neurol. 2009, 68:994-1005.
60. Hinkle K.M., Yue M., Behrouz B., Dachsel J.C., Lincoln S.J., Bowles E.E., Beevers J.E., Dugger B., Winner B., Prots I., Kent C.B., Nishioka K., Lin W.L., Dickson D.W., Janus C.J., Farrer M.J., Melrose H.L. LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol. Neurodegener. 2012, 7:25.
61. Hsu C.H., Chan D., Greggio E., Saha S., Guillily M.D., Ferree A., Raghavan K., Shen G.C., Segal L., Ryu H., Cookson M.R., Wolozin B. MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J. Neurochem. 2010, 112:1593-1604.
62. Hulihan M.M., Ishihara-Paul L., Kachergus J., Warren L., Amouri R., Elango R., Prinjha R.K., Upmanyu R., Kefi M., Zouari M., Sassi S.B., Yahmed S.B., El Euch-Fayeche G., Matthews P.M., Middleton L.T., Gibson R.A., Hentati F., Farrer M.J. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. Lancet Neurol. 2008, 7:591-594.
63. Hurley M.J., Patel P.H., Jackson M.J., Smith L.A., Rose S., Jenner P. Striatal leucine-rich repeat kinase 2 mRNA is increased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned common marmosets (Callithrix jacchus) with L-3, 4-dihydroxyphenylalanine methyl ester-induced dyskinesia. Eur. J. Neurosci. 2007, 26:171-177.
64. Iaccarino C., Crosio C., Vitale C., Sanna G., Carri M.T., Barone P. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum. Mol. Genet. 2007, 16:1319-1326.
65. Imai Y., Gehrke S., Wang H.Q., Takahashi R., Hasegawa K., Oota E., Lu B. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 2008, 27:2432-2443.
66. Imamura K., Hishikawa N., Sawada M., Nagatsu T., Yoshida M., Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 2003, 106:518-526.
67. Jaleel M., Nichols R.J., Deak M., Campbell D.G., Gillardon F., Knebel A., Alessi D.R. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 2007, 405:307-317.
68. Jorgensen N.D., Peng Y., Ho C.C., Rideout H.J., Petrey D., Liu P., Dauer W.T. The WD40 domain is required for LRRK2 neurotoxicity. PLoS One 2009, 4:e8463.
69. Kamikawaji S., Ito G., Iwatsubo T. Identification of the autophosphorylation sites of LRRK2. Biochemistry 2009, 48:10963-10975.
70. Kawakami F., Yabata T., Ohta E., Maekawa T., Shimada N., Suzuki M., Maruyama H., Ichikawa T., Obata F. LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS One 2012, 7:e30834.
71. Kay D.M., Kramer P., Higgins D., Zabetian C.P., Payami H. Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. Mov. Disord. 2005, 20:1077-1078.
72. Kett L.R., Boassa D., Ho C.C., Rideout H.J., Hu J., Terada M., Ellisman M., Dauer W.T. LRRK2 Parkinson disease mutations enhance its microtubule association. Hum. Mol. Genet. 2012, 21:890-899.
73. Kim B., Yang M.S., Choi D., Kim J.H., Kim H.S., Seol W., Choi S., Jou I., Kim E.Y., Joe E.H. Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One 2012, 7:e34693.
74. Ko H.S., Bailey R., Smith W.W., Liu Z., Shin J.H., Lee Y.I., Zhang Y.J., Jiang H., Ross C.A., Moore D.J., Patterson C., Petrucelli L., Dawson T.M., Dawson V.L. CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2897-2902.
75. Kondo K., Obitsu S., Teshima R. alpha-Synuclein aggregation and transmission are enhanced by leucine-rich repeat kinase 2 in human neuroblastoma SH-SY5Y cells. Biol. Pharm. Bull. 2011, 34:1078-1083.
76. Kubo M., Kamiya Y., Nagashima R., Maekawa T., Eshima K., Azuma S., Ohta E., Obata F. LRRK2 is expressed in B-2 but not in B-1 B cells, and downregulated by cellular activation. J. Neuroimmunol. 2010, 229:123-128.
77. Kumar A., Cookson M.R. Role of LRRK2 kinase dysfunction in Parkinson disease. Expert Rev. Mol. Med. 2011, 13:e20.
78. Kuss M., Adamopoulou E., Kahle P.J. Interferon-gamma induces leucine-rich repeat kinase LRRK2 via extracellular signal-regulated kinase ERK5 in macrophages. J. Neurochem. 2014.
79. Latourelle J.C., Sun M., Lew M.F., Suchowersky O., Klein C., Golbe L.I., Mark M.H., Growdon J.H., Wooten G.F., Watts R.L., Guttman M., Racette B.A., Perlmutter J.S., Ahmed A., Shill H.A., Singer C., Goldwurm S., Pezzoli G., Zini M., Saint-Hilaire M.H., Hendricks A.E., Williamson S., Nagle M.W., Wilk J.B., Massood T., Huskey K.W., Laramie J.M., DeStefano A.L., Baker K.B., Itin I., Litvan I., Nicholson G., Corbett A., Nance M., Drasby E., Isaacson S., Burn D.J., Chinnery P.F., Pramstaller P.P., Al-hinti J., Moller A.T., Ostergaard K., Sherman S.J., Roxburgh R., Snow B., Slevin J.T., Cambi F., Gusella J.F., Myers R.H. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med. 2008, 6:32.
80. Law B.M., Spain V.A., Leinster V.H., Chia R., Beilina A., Cho H.J., Taymans J.M., Urban M.K., Sancho R.M., Blanca Ramirez M., Biskup S., Baekelandt V., Cai H., Cookson M.R., Berwick D.C., Harvey K. A direct interaction between Leucine-rich Repeat Kinase 2 and specific beta-tubulin isoforms regulates tubulin acetylation. J. Biol. Chem. 2013, 289(2):895-908.
81. Lee B.D., Dawson V.L., Dawson T.M. Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. Trends Pharmacol. Sci. 2012, 33:365-373.
82. Li X., Tan Y.C., Poulose S., Olanow C.W., Huang X.Y., Yue Z. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J. Neurochem. 2007, 103:238-247.
83. Li Y., Liu W., Oo T.F., Wang L., Tang Y., Jackson-Lewis V., Zhou C., Geghman K., Bogdanov M., Przedborski S., Beal M.F., Burke R.E., Li C. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 2009, 12:826-828.
84. Li X., Moore D.J., Xiong Y., Dawson T.M., Dawson V.L. Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2. J. Biol. Chem. 2010, 285:29569-29576.
85. Li X., Patel J.C., Wang J., Avshalumov M.V., Nicholson C., Buxbaum J.D., Elder G.A., Rice M.E., Yue Z. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J. Neurosci. 2010, 30:1788-1797.
86. Li X., Wang Q.J., Pan N., Lee S., Zhao Y., Chait B.T., Yue Z. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One 2011, 6:e17153.
87. Lichtenberg M., Mansilla A., Zecchini V.R., Fleming A., Rubinsztein D.C. The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity. Cell Death Dis. 2011, 2:e196.
88. Lin X., Parisiadou L., Gu X.L., Wang L., Shim H., Sun L., Xie C., Long C.X., Yang W.J., Ding J., Chen Z.Z., Gallant P.E., Tao-Cheng J.H., Rudow G., Troncoso J.C., Liu Z., Li Z., Cai H. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 2009, 64:807-827.
89. Lin C.H., Tsai P.I., Wu R.M., Chien C.T. LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ss. J. Neurosci. 2010, 30:13138-13149.
90. Liou A.K., Leak R.K., Li L., Zigmond M.J. Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway. Neurobiol. Dis. 2008, 32:116-124.
91. Liu M., Dobson B., Glicksman M.A., Yue Z., Stein R.L. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. Biochemistry 2010, 49:2008-2017.
92. Liu Z., Hamamichi S., Lee B.D., Yang D., Ray A., Caldwell G.A., Caldwell K.A., Dawson T.M., Smith W.W., Dawson V.L. Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Hum. Mol. Genet. 2011, 20:3933-3942.
93. Liu Z., Lee J., Krummey S., Lu W., Cai H., Lenardo M.J. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat. Immunol. 2011, 12:1063-1070.
94. Lopez de Maturana R., Aguila J.C., Sousa A., Vazquez N., Del Rio P., Aiastui A., Gorostidi A., Lopez de Munain A., Sanchez-Pernaute R. Leucine-rich repeat kinase 2 modulates cyclooxygenase 2 and the inflammatory response in idiopathic and genetic Parkinson's disease. Neurobiol. Aging 2013, 35(5):1116-1124.
95. Luerman G.C., Nguyen C., Samaroo H., Loos P., Xi H., Hurtado-Lorenzo A., Needle E., Stephen Noell G., Galatsis P., Dunlop J., Geoghegan K.F., Hirst W.D. Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J. Neurochem. 2013, 128(4):561-576.
96. Luzon-Toro B., Rubio de la Torre E., Delgado A., Perez-Tur J., Hilfiker S. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum. Mol. Genet. 2007, 16:2031-2039.
97. MacLeod D., Dowman J., Hammond R., Leete T., Inoue K., Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006, 52:587-593.
98. Maekawa T., Kubo M., Yokoyama I., Ohta E., Obata F. Age-dependent and cell-population-restricted LRRK2 expression in normal mouse spleen. Biochem. Biophys. Res. Commun. 2010, 392:431-435.
99. Maekawa T., Mori S., Sasaki Y., Miyajima T., Azuma S., Ohta E., Obata F. The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities. Mol. Neurodegener. 2012, 7:15.
100. Mamais A., Raja M., Manzoni C., Dihanich S., Lees A., Moore D., Lewis P.A., Bandopadhyay R. Divergent alpha-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases. Neurobiol. Dis. 2013, 58:183-190.
101. Mangeat P., Roy C., Martin M. ERM proteins in cell adhesion and membrane dynamics: authors' correction. Trends Cell Biol. 1999, 9:289.
102. Manzoni C., Mamais A., Dihanich S., Abeti R., Soutar M.P., Plun-Favreau H., Giunti P., Tooze S.A., Bandopadhyay R., Lewis P.A. Inhibition of LRRK2 kinase activity stimulates macroautophagy. Biochim. Biophys. Acta 2013, 1833:2900-2910.
103. Manzoni C., Mamais A., Dihanich S., McGoldrick P., Devine M.J., Zerle J., Kara E., Taanman J.W., Healy D.G., Marti-Masso J.F., Schapira A.H., Plun-Favreau H., Tooze S., Hardy J., Bandopadhyay R., Lewis P.A. Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation. Biochem. Biophys. Res. Commun. 2013, 441:862-866.
104. Mata I.F., Checkoway H., Hutter C.M., Samii A., Roberts J.W., Kim H.M., Agarwal P., Alvarez V., Ribacoba R., Pastor P., Lorenzo-Betancor O., Infante J., Sierra M., Gomez-Garre P., Mir P., Ritz B., Rhodes S.L., Colcher A., Van Deerlin V., Chung K.A., Quinn J.F., Yearout D., Martinez E., Farin F.M., Wan J.Y., Edwards K.L., Zabetian C.P. Common variation in the LRRK2 gene is a risk factor for Parkinson's disease. Mov. Disord. 2012, 27:1823-1826.
105. Matta S., Van Kolen K., da Cunha R., van den Bogaart G., Mandemakers W., Miskiewicz K., De Bock P.J., Morais V.A., Vilain S., Haddad D., Delbroek L., Swerts J., Chavez-Gutierrez L., Esposito G., Daneels G., Karran E., Holt M., Gevaert K., Moechars D.W., De Strooper B., Verstreken P. LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron 2012, 75:1008-1021.
106. Meixner A., Boldt K., Van Troys M., Askenazi M., Gloeckner C.J., Bauer M., Marto J.A., Ampe C., Kinkl N., Ueffing M. A QUICK screen for Lrrk2 interaction partners-leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics. Mol. Cell. Proteomics 2011, 10. (M110 001172).
107. Melrose H. Update on the functional biology of Lrrk2. Future Neurol. 2008, 3:669-681.
108. Melrose H.L., Dachsel J.C., Behrouz B., Lincoln S.J., Yue M., Hinkle K.M., Kent C.B., Korvatska E., Taylor J.P., Witten L., Liang Y.Q., Beevers J.E., Boules M., Dugger B.N., Serna V.A., Gaukhman A., Yu X., Castanedes-Casey M., Braithwaite A.T., Ogholikhan S., Yu N., Bass D., Tyndall G., Schellenberg G.D., Dickson D.W., Janus C., Farrer M.J. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol. Dis. 2010, 40:503-517.
109. Moehle M.S., Webber P.J., Tse T., Sukar N., Standaert D.G., DeSilva T.M., Cowell R.M., West A.B. LRRK2 inhibition attenuates microglial inflammatory responses. J. Neurosci. 2012, 32:1602-1611.
110. Mortiboys H., Johansen K.K., Aasly J.O., Bandmann O. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 2010, 75:2017-2020.
111. Mutez E., Larvor L., Lepretre F., Mouroux V., Hamalek D., Kerckaert J.P., Perez-Tur J., Waucquier N., Vanbesien-Mailliot C., Duflot A., Devos D., Defebvre L., Kreisler A., Frigard B., Destee A., Chartier-Harlin M.C. Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation. Neurobiol. Aging 2011, 32:1839-1848.
112. Mutez E., Nkiliza A., Belarbi K., de Broucker A., Vanbesien-Mailliot C., Bleuse S., Duflot A., Comptdaer T., Semaille P., Blervaque R., Hot D., Lepretre F., Figeac M., Destee A., Chartier-Harlin M.C. Involvement of the immune system, endocytosis and EIF2 signaling in both genetically determined and sporadic forms of Parkinson's disease. Neurobiol. Dis. 2014, 63:165-170.
113. Narendra D., Tanaka A., Suen D.F., Youle R.J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 2008, 183:795-803.
114. Ng C.H., Mok S.Z., Koh C., Ouyang X., Fivaz M.L., Tan E.K., Dawson V.L., Dawson T.M., Yu F., Lim K.L. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J. Neurosci. 2009, 29:11257-11262.
115. Nichols R.J., Dzamko N., Morrice N.A., Campbell D.G., Deak M., Ordureau A., Macartney T., Tong Y., Shen J., Prescott A.R., Alessi D.R. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem. J. 2010, 430:393-404.
116. Niu J., Yu M., Wang C., Xu Z. Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via dynamin-like protein. J. Neurochem. 2012, 122:650-658.
117. Orenstein S.J., Kuo S.H., Tasset I., Arias E., Koga H., Fernandez-Carasa I., Cortes E., Honig L.S., Dauer W., Consiglio A., Raya A., Sulzer D., Cuervo A.M. Interplay of LRRK2 with chaperone-mediated autophagy. Nat. Neurosci. 2013, 16(4):394-406.
118. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Marti-Masso J.F., Perez-Tur J., Wood N.W., Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
119. Paisan-Ruiz C., Nath P., Washecka N., Gibbs J.R., Singleton A.B. Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls. Hum. Mutat. 2008, 29:485-490.
120. Papkovskaia T.D., Chau K.Y., Inesta-Vaquera F., Papkovsky D.B., Healy D.G., Nishio K., Staddon J., Duchen M.R., Hardy J., Schapira A.H., Cooper J.M. G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. Hum. Mol. Genet. 2012, 21:4201-4213.
121. Parisiadou L., Cai H. LRRK2 function on actin and microtubule dynamics in Parkinson disease. Commun. Integr. Biol. 2010, 3:396-400.
122. Parisiadou L., Xie C., Cho H.J., Lin X., Gu X.L., Long C.X., Lobbestael E., Baekelandt V., Taymans J.M., Sun L., Cai H. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J. Neurosci. 2009, 29:13971-13980.
123. Perry G., Zhu X., Babar A.K., Siedlak S.L., Yang Q., Ito G., Iwatsubo T., Smith M.A., Chen S.G. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies. Neurodegener. Dis. 2008, 5:222-224.
124. Piccoli G., Condliffe S.B., Bauer M., Giesert F., Boldt K., De Astis S., Meixner A., Sarioglu H., Vogt-Weisenhorn D.M., Wurst W., Gloeckner C.J., Matteoli M., Sala C., Ueffing M. LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J. Neurosci. 2011, 31:2225-2237.
125. Plowey E.D., Cherra S.J., Liu Y.J., Chu C.T. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J. Neurochem. 2008, 105:1048-1056.
126. Poulopoulos M., Cortes E., Vonsattel J.P., Fahn S., Waters C., Cote L.J., Moskowitz C., Honig L.S., Clark L.N., Marder K.S., Alcalay R.N. Clinical and pathological characteristics of LRRK2 G2019S patients with PD. J. Mol. Neurosci. 2012, 47:139-143.
127. Qin L., Wu X., Block M.L., Liu Y., Breese G.R., Hong J.S., Knapp D.J., Crews F.T. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462.
128. Qing H., Wong W., McGeer E.G., McGeer P.L. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem. Biophys. Res. Commun. 2009, 387:149-152.
129. Qing H., Zhang Y., Deng Y., McGeer E.G., McGeer P.L. Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease. Biochem. Biophys. Res. Commun. 2009, 390:1229-1234.
130. Ramonet D., Daher J.P., Lin B.M., Stafa K., Kim J., Banerjee R., Westerlund M., Pletnikova O., Glauser L., Yang L., Liu Y., Swing D.A., Beal M.F., Troncoso J.C., McCaffery J.M., Jenkins N.A., Copeland N.G., Galter D., Thomas B., Lee M.K., Dawson T.M., Dawson V.L., Moore D.J. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 2011, 6:e18568.
131. Ray S., Liu M. Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design. Future Med. Chem. 2012, 4:1701-1713.
132. Rudenko I.N., Cookson M.R. 14-3-3 proteins are promising LRRK2 interactors. Biochem. J. 2010, 430:e5-e6.
133. Rudenko I.N., Chia R., Cookson M.R. Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?. BMC Med. 2012, 10:20.
134. Saha S., Guillily M.D., Ferree A., Lanceta J., Chan D., Ghosh J., Hsu C.H., Segal L., Raghavan K., Matsumoto K., Hisamoto N., Kuwahara T., Iwatsubo T., Moore L., Goldstein L., Cookson M., Wolozin B. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J. Neurosci. 2009, 29:9210-9218.
135. Samann J., Hegermann J., von Gromoff E., Eimer S., Baumeister R., Schmidt E. Caenorhabditis elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J. Biol. Chem. 2009, 284:16482-16491.
136. Sanchez-Danes A., Richaud-Patin Y., Carballo-Carbajal I., Jimenez-Delgado S., Caig C., Mora S., Di Guglielmo C., Ezquerra M., Patel B., Giralt A., Canals J.M., Memo M., Alberch J., Lopez-Barneo J., Vila M., Cuervo A.M., Tolosa E., Consiglio A., Raya A. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol. Med. 2012, 4:380-395.
137. Satake W., Nakabayashi Y., Mizuta I., Hirota Y., Ito C., Kubo M., Kawaguchi T., Tsunoda T., Watanabe M., Takeda A., Tomiyama H., Nakashima K., Hasegawa K., Obata F., Yoshikawa T., Kawakami H., Sakoda S., Yamamoto M., Hattori N., Murata M., Nakamura Y., Toda T. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 2009, 41:1303-1307.
138. Sen S., Webber P.J., West A.B. Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. J. Biol. Chem. 2009, 284:36346-36356.
139. Seol W. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease. BMB Rep. 2010, 43:233-244.
140. Sheng Z., Zhang S., Bustos D., Kleinheinz T., Le Pichon C.E., Dominguez S.L., Solanoy H.O., Drummond J., Zhang X., Ding X., Cai F., Song Q., Li X., Yue Z., van der Brug M.P., Burdick D.J., Gunzner-Toste J., Chen H., Liu X., Estrada A.A., Sweeney Z.K., Scearce-Levie K., Moffat J.G., Kirkpatrick D.S., Zhu H. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci. Transl. Med. 2012, 4:164ra161.
141. Shin N., Jeong H., Kwon J., Heo H.Y., Kwon J.J., Yun H.J., Kim C.H., Han B.S., Tong Y., Shen J., Hatano T., Hattori N., Kim K.S., Chang S., Seol W. LRRK2 regulates synaptic vesicle endocytosis. Exp. Cell Res. 2008, 314:2055-2065.
142. Simon-Sanchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., Paisan-Ruiz C., Lichtner P., Scholz S.W., Hernandez D.G., Kruger R., Federoff M., Klein C., Goate A., Perlmutter J., Bonin M., Nalls M.A., Illig T., Gieger C., Houlden H., Steffens M., Okun M.S., Racette B.A., Cookson M.R., Foote K.D., Fernandez H.H., Traynor B.J., Schreiber S., Arepalli S., Zonozi R., Gwinn K., van der Brug M., Lopez G., Chanock S.J., Schatzkin A., Park Y., Hollenbeck A., Gao J., Huang X., Wood N.W., Lorenz D., Deuschl G., Chen H., Riess O., Hardy J.A., Singleton A.B., Gasser T. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 2009, 41:1308-1312.
143. Skibinski G., Nakamura K., Cookson M.R., Finkbeiner S. Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. J. Neurosci. 2014, 34:418-433.
144. Smith J.A., Francis S.H., Corbin J.D. Autophosphorylation: a salient feature of protein kinases. Mol. Cell. Biochem. 1993, 127-128:51-70.
145. Smith W.W., Pei Z., Jiang H., Moore D.J., Liang Y., West A.B., Dawson V.L., Dawson T.M., Ross C.A. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18676-18681.
146. Smith W.W., Pei Z., Jiang H., Dawson V.L., Dawson T.M., Ross C.A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 2006, 9:1231-1233.
147. Tan E.K., Jankovic J. Genetic testing in Parkinson disease: promises and pitfalls. Arch. Neurol. 2006, 63:1232-1237.
148. Taymans J.M., Vancraenenbroeck R., Ollikainen P., Beilina A., Lobbestael E., De Maeyer M., Baekelandt V., Cookson M.R. LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. PLoS One 2011, 6:e23207.
149. Thevenet J., Pescini Gobert R., Hooft van Huijsduijnen R., Wiessner C., Sagot Y.J. Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS One 2011, 6:e21519.
150. Tong Y., Pisani A., Martella G., Karouani M., Yamaguchi H., Pothos E.N., Shen J. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14622-14627.
151. Tong Y., Yamaguchi H., Giaime E., Boyle S., Kopan R., Kelleher R.J., Shen J. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:9879-9884.
152. Tong Y., Giaime E., Yamaguchi H., Ichimura T., Liu Y., Si H., Cai H., Bonventre J.V., Shen J. Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol. Neurodegener. 2012, 7:2.
153. Tsika E., Moore D.J. Mechanisms of LRRK2-mediated neurodegeneration. Curr. Neurol. Neurosci. Rep. 2012, 12:251-260.
154. Venderova K., Kabbach G., Abdel-Messih E., Zhang Y., Parks R.J., Imai Y., Gehrke S., Ngsee J., Lavoie M.J., Slack R.S., Rao Y., Zhang Z., Lu B., Haque M.E., Park D.S. Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Hum. Mol. Genet. 2009, 18:4390-4404.
155. Vitte J., Traver S., Maues De Paula A., Lesage S., Rovelli G., Corti O., Duyckaerts C., Brice A. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease. J. Neuropathol. Exp. Neurol. 2010, 69:959-972.
156. Wang L., Xie C., Greggio E., Parisiadou L., Shim H., Sun L., Chandran J., Lin X., Lai C., Yang W.J., Moore D.J., Dawson T.M., Dawson V.L., Chiosis G., Cookson M.R., Cai H. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J. Neurosci. 2008, 28:3384-3391.
157. Wang X., Yan M.H., Fujioka H., Liu J., Wilson-Delfosse A., Chen S.G., Perry G., Casadesus G., Zhu X. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum. Mol. Genet. 2012, 21:1931-1944.
158. Webber P.J., Smith A.D., Sen S., Renfrow M.B., Mobley J.A., West A.B. Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. J. Mol. Biol. 2011, 412:94-110.
159. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., Dawson T.M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:16842-16847.
160. West A.B., Moore D.J., Choi C., Andrabi S.A., Li X., Dikeman D., Biskup S., Zhang Z., Lim K.L., Dawson V.L., Dawson T.M. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 2007, 16:223-232.
161. Westerlund M., Ran C., Borgkvist A., Sterky F.H., Lindqvist E., Lundstromer K., Pernold K., Brene S., Kallunki P., Fisone G., Olson L., Galter D. Lrrk2 and alpha-synuclein are co-regulated in rodent striatum. Mol. Cell. Neurosci. 2008, 39:586-591.
162. Xiong Y.L., Coombes C.E., Kilaru A., Li X., Gitler A.D., Bowers W.J., Dawson V.L., Dawson T.M., Moore D.J. GTPase activity plays a key role in the pathobiology of LRRK2. Plos Genet. 2010, 6.
163. Xiong Y., Yuan C., Chen R., Dawson T.M., Dawson V.L. ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2. J. Neurosci. 2012, 32:3877-3886.
164. Yacoubian T.A., Slone S.R., Harrington A.J., Hamamichi S., Schieltz J.M., Caldwell K.A., Caldwell G.A., Standaert D.G. Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease. Cell Death Dis. 2010, 1:e2.
165. Yao C., Johnson W.M., Gao Y., Wang W., Zhang J., Deak M., Alessi D.R., Zhu X., Mieyal J.J., Roder H., Wilson-Delfosse A.L., Chen S.G. Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity. Hum. Mol. Genet. 2013, 22:328-344.
166. Zhao J., Hermanson S.B., Carlson C.B., Riddle S.M., Vogel K.W., Bi K., Nichols R.J. Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology. Biochem. Soc. Trans. 2012, 40:1158-1162.
167. Zhou H., Huang C., Tong J., Hong W.C., Liu Y.J., Xia X.G. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int. J. Biol. Sci. 2011, 7:753-761.
168. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.